The Astellas chief commercial officer discusses the impact that the increase in global and local connectivity has had on commercialization, among other trends.

The latest news for pharma industry insiders.

CSL and Artcurus announced the results of a study on the self-amplifying RNA vaccine.

Flyrcado is the first positron emission tomography myocardial perfusion imaging agent of its kind designed for the detection of coronary artery disease.

Designed for cataract patients, the TECNIS Odyssey aims to reduce the need for glasses by offering a full range of precise vision at all distances.

The latest news for pharma industry insiders.

Corcoran is using her family’s personal story with the disease to promote awareness.

In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses what specific areas of research and development are likely to benefit the most from this influx of of venture capital and federal funding.

Dupixent was found to significantly reduce the rate of moderate to severe exacerbations of chronic obstructive pulmonary disease, according to data from the Phase III BOREAS and NOTUS trials.

Landmark FDA approval of Cobenfy represents the first new class of drugs indicated to treat schizophrenia in decades.

A Harvard Business School Healthcare Alumni Association Q&A with Martin Gonzalez, Principal of Org and Leadership Development at Google.

In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, discusses strategies companies employ to effectively identify and dispose of non-core assets while minimizing disruption to their operations.

The latest news for pharma industry insiders.

Murphy previously worked at the Biotechnology Innovation Organization as its chief policy officer.

The program, Rx-Performance, will be available starting in January of next year.

A new JAMA study indicates that semaglutide produced up to a 68% lower risk of opioid overdose for patients with type 2 diabetes compared to other antidiabetic medications.

Tagrisso was approved under a Priority Review based on the pivotal LAURA Phase III trial in adults with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer.

The anti-obesity drug maker is raising awareness about the struggle that constant thoughts about food can have on people trying to manage their weight.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview,Jonathan Scheinberg, of the Northeast Science and Technology Center, talks about strategies companies can adopt to attract and retain top talent in these competitive mega campus locations.

The Calliditas Therapeutics CEO discusses her transition from a banker/investor to CEO of a pharma company.

Omnichannel marketing can help companies improve HCP engagement to facilitate the delivery of effective treatment to patients who desperately need and deserve it.

The legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer's drug development, leading to securities litigation over allegedly misleading statements about trial results and commercialization efforts.

The Octave Bioscience CEO discusses leading the company through commercialization and expansion.

The latest news for pharma industry insiders.